Видео ютуба по тегу Nct03390504

Elucidating the biology of upper tract urothelial cancer
Elucidating the biology of upper tract urothelial cancer
What are the current and emerging biomarkers in urothelial carcinoma?
What are the current and emerging biomarkers in urothelial carcinoma?
THOR: erdafitinib in advanced or metastatic urothelial cancer and FGFR alterations
THOR: erdafitinib in advanced or metastatic urothelial cancer and FGFR alterations
THOR: erdafitinib in metastatic urothelial cancer with FGFR alterations
THOR: erdafitinib in metastatic urothelial cancer with FGFR alterations
How can we best sequence novel treatments in urothelial cancer?
How can we best sequence novel treatments in urothelial cancer?
The future role of erdafitinib in advanced urothelial carcinoma
The future role of erdafitinib in advanced urothelial carcinoma
An update on erdafitinib for metastatic/uresectable FGFR alteration urothelial carcinoma
An update on erdafitinib for metastatic/uresectable FGFR alteration urothelial carcinoma
Phase III THOR study: erdafitinib vs. pembrolizumab in FGFR-altered advanced or metastatic UC
Phase III THOR study: erdafitinib vs. pembrolizumab in FGFR-altered advanced or metastatic UC
Treatment options for mUC following chemo-immunotherapy failure
Treatment options for mUC following chemo-immunotherapy failure
What role will erdafitinib play in treating metastatic urothelial carcinoma?
What role will erdafitinib play in treating metastatic urothelial carcinoma?
Erdafitinib for bladder cancer: more to come following FDA approval
Erdafitinib for bladder cancer: more to come following FDA approval
THOR: impact of FGFR3 alterations in mUC on subtype and outcomes with erdafitinib vs pembrolizumab
THOR: impact of FGFR3 alterations in mUC on subtype and outcomes with erdafitinib vs pembrolizumab
Managing toxicities in advanced urothelial cancers: insights on EV and erdafitinib
Managing toxicities in advanced urothelial cancers: insights on EV and erdafitinib